A woman charged with selling Matthew Perry the dose of ketamine that killed him is headed for a September trial.
Jasveen Sangha's trial the only one forthcoming in the death of the Friends star after four other defendants reached plea agreements with prosecutors is now set to begin September 23 after an order Tuesday from a federal judge in Los Angeles.
The 42-year-old Sangha, who prosecutors say was known to her customers as The Ketamine Queen, is charged with five counts of ketamine distribution, including one count of distribution resulting in death. She has pleaded not guilty and has been held in federal custody since her arrest last year.
Her trial had been scheduled to start August 19, but the judge postponed it for the fourth time since her April 2024 indictment after both sides agreed it should be moved.
Sangha's lawyers said they needed the time to go through the huge amount of evidence they have received from the prosecution and to finish their own investigation.
Sangha was one of the two biggest targets in the investigation of Perry's death, along with Dr. Salvador Plasencia, who pleaded guilty to ketamine distribution last month. Perry's personal assistant, his friend and another doctor also entered guilty pleas and are cooperating with prosecutors. All are awaiting sentencing.
Perry, who was found dead at age 54 at his home on October 23, 2023, had been getting ketamine from his regular doctor for treatment of depression, an increasingly common off-label use for the surgical anesthetic.
But prosecutors say when the doctor wouldn't give Perry as much as he wanted, he illegally sought more from Plasencia, then still more from Sangha, who they say presented herself as "a celebrity drug dealer with high quality goods.
Perry's assistant and friend said in their plea agreements that they acted as middlemen to buy large amounts of ketamine for Perry from Sangha, including 25 vials for USD 6,000 in cash a few days before his death. Prosecutors allege that included the doses that killed Perry.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)